Alkermes (ALKS) reported $1.5B in revenue for fiscal 2025, −5.2% year on year. That ranks #1522 by revenue among 2853 SEC filers and #136 in Healthcare. Net income was $242M, a net margin of 16.4%. Revenue has grown 7.9% a year on average since 2016 ($746M then). The fiscal 2025 balance sheet shows $2.5B in total assets, $389M in cash and $0 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $1.5B | −5.2% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $254M | −39.6% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $242M | −34.2% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $521M | +18.6% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $40.4M | +20.7% | FY20252025-12-31 |
| Total assetsAssets | $2.5B | +21.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.8B | +24.2% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $389M | +33.5% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $0 | −100.0% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $393M | −$66.5M | Open → |
| Q2 20262026-06-30 | $496M | $501,000 | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 35 of 161 companies compared | 16.4% | |
| Operating marginRank 47 of 160 companies compared | 17.2% | |
| R&D as share of revenueRank 22 of 102 companies compared | 22.0% | |
| Cash as share of revenueRank 32 of 160 companies compared | 26.3% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Alkermes Plc.
- Ticker
- ALKS
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001520262
Filings
- 10-QJul 28, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KFeb 25, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| National HealthcareNHC | $1.5B | $120M |
| Merit Medical SystemsMMSI | $1.5B | $128M |
| Nu Skin EnterprisesNUS | $1.5B | $160M |
| AlkermesALKS | $1.5B | $242M |
| P3 Health PartnersPIII | $1.5B | −$148M |
| Guardian Pharmacy ServicesGRDN | $1.4B | $49.2M |
| TrupanionTRUP | $1.4B | $19.4M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Alkermes — Key figures |url=https://companiesranked.com/en/company/alkermes |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Alkermes — Key figures. CompaniesRanked. https://companiesranked.com/en/company/alkermesBibTeX
@misc{companiesranked-en-company-alkermes-2026,
author = {{CompaniesRanked}},
title = {{Alkermes — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/alkermes}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-068925 · February 25, 2026
{{cite web |title=Alkermes — Key figures — 10-K (0001193125-26-068925) |url=https://www.sec.gov/Archives/edgar/data/1520262/000119312526068925/alks-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.